ADC Deals Are Up 1900% in 2026 — Here's the Data

Twenty ADC deals closed between March 1 and August 29, 2026 — a 1900% increase over the single deal recorded in the prior six-month window (September 2025 to March 2026). This is not a gentle uptick. This is a market that went from functionally dormant to white-hot in under two quarters, driven by Big Pharma's urgent need to backfill late-stage oncology pipelines after a string of LOE cliffs and the commercial validation of next-generation ADC payloads and linker chemistries.

The Data — ADC Deal Activity, Period over Period

The raw percentage is eye-catching, and yes, the low base inflates the figure. But 20 ADC licensing deals in six months is structurally meaningful by any standard. For context, DealForma tracked roughly 30 ADC-related deals across all of 2024. We have already surpassed two-thirds of that annual pace in half the time. ADC deal trends 2026 are not a statistical artifact — they reflect a fundamental reallocation of BD capital toward this modality.

What's Driving the Trend

Pipeline desperation meets clinical proof points. The first driver is straightforward: multiple large-cap pharma companies face combined revenue exposure north of $80B in LOE risk between 2027 and 2030. Keytruda alone represents a $25B+ hole for Merck. ADCs, with their demonstrated ability to generate differentiated clinical profiles in crowded tumor types, are the fastest path to pipeline replenishment that doesn't require a full M&A process. Licensing is faster, cheaper on a risk-adjusted basis, and lets acquirers cherry-pick specific targets rather than buying entire organizations.

The technology has matured past the hype cycle. Enhertu's multi-indication expansion proved the commercial thesis. But what's catalyzing ADC licensing 2026 activity specifically is the second wave of enabling technologies — site-specific conjugation, novel topoisomerase inhibitor payloads, immunostimulatory warheads, and bispecific ADC architectures. These aren't incremental improvements. They open new target spaces (low-expression antigens, solid tumors with poor internalization) that first-generation ADCs couldn't address. Pharma BD teams aren't just buying molecules — they're buying access to platform chemistry that generates multiple shots on goal.

Capital markets are pushing biotech founders to transact. The IPO window for preclinical-stage ADC companies has been unreliable through 2025 and into 2026. Many platform-stage biotechs that would have preferred to IPO at a $500M+ valuation are instead licensing lead programs to fund their operations and validate their platforms. This dynamic creates a buyer-friendly environment on individual asset terms, even as overall deal volume surges. You can see this in the deal structures: large total deal values paired with modest or undisclosed upfronts, heavy milestone loading, and broad territory grants. Compare this with Deal Benchmarks from 2023-2024, when ADC upfronts routinely cleared $100M+ for comparable-stage assets.

Notable Deals

GSK-Hansoh ($185M upfront / $1.7B TDV) is the anchor transaction and the clearest signal of market pricing. GSK paid the highest disclosed upfront in this cohort — $185M — for a Hansoh ADC program. The $1.7B total deal value implies a roughly 11% upfront-to-TDV ratio, which sits on the lower end of historical ADC benchmarks. GSK is buying clinical de-risking at scale, consistent with its stated strategy to build a differentiated oncology portfolio post-Zejula. This deal sets the ceiling for upfront pricing in the current cycle.

Novartis-Myricx Bio (two deals, $1.1B and $1.5B TDV) represents something more interesting: a multi-program platform bet. Novartis signed two separate agreements with Myricx on the same day, totaling $2.6B in potential deal value — but with no disclosed upfronts. This structure screams early-stage, platform-driven optionality. Novartis is paying in milestones for access to Myricx's conjugation technology across multiple targets. It's a capital-efficient way to build ADC pipeline breadth without committing large upfronts to unproven assets. For biotech founders evaluating Solidus to model their own deal economics, this is the template that dominates 2026: big headlines, back-loaded economics.

Biocytogen-Whitehawk (two deals, one at $500M TDV) follows a similar pattern. Whitehawk, a less prominent licensee, is taking positions in Biocytogen's RenMab-derived ADC pipeline. The undisclosed upfronts and modest TDV suggest these are earlier-stage assets, likely preclinical or early Phase I. The deals signal that ADC demand has expanded beyond the top-five pharma buyers to include specialty and mid-cap acquirers — a classic sign of a maturing deal market.

What This Means for BD Teams Right Now

If you're selling: you have leverage, but it's perishable. Twenty deals in six months means there's real competitive tension among buyers. But the data also shows that upfronts are compressed relative to TDV. Buyers are not panicking into large upfronts — they're using milestone-heavy structures to manage risk. If you're a biotech with differentiated ADC technology and clinical data, this is the window to run a competitive process. Push for upfronts in the $100M-$200M range for clinical-stage assets, and don't accept sub-10% upfront-to-TDV ratios unless you're genuinely preclinical. The Hansoh-GSK deal gives you a credible comp to anchor negotiations.

If you're buying: move now, but structure defensively. The ADC asset pool at the quality frontier is finite. Every deal that closes removes a potential target. The Novartis-Myricx template — multiple programs, heavy milestone loading, platform access — is the right playbook. Lock up optionality across several targets rather than paying premium upfronts for a single program. The risk of waiting is not that prices increase (milestone structures cap your downside) — it's that the best platforms get taken off the market entirely.

Deal structures to watch: Co-development and co-commercialization rights are becoming more common in ADC licensing 2026, particularly for assets targeting high-value indications (breast, lung, gastric). Opt-in structures after Phase I data readouts let buyers manage risk while securing access. Royalty rates are trending toward the 10-15% range for preclinical deals and 15-20%+ for clinical-stage, consistent with the data on Deal Benchmarks.

Benchmark your deal against current market rates. Whether you're structuring an ADC out-license or evaluating an inbound term sheet, the economics shift quarter to quarter. Use the Ambrosia calculator to stress-test your upfront, milestones, royalties, and total deal value against the latest closed transactions.